Loading…

Matrix metalloproteinase-9 (MMP-9) expression in childhood osseous osteosarcoma

Background Over 80% of patients with osteosarcoma treated with excision alone develop pulmonary metastases, suggesting that the majority of patients with this disease harbor “micrometastases” at diagnosis. There are no histologic or molecular variables which can predict the presence or absence of mi...

Full description

Saved in:
Bibliographic Details
Published in:Medical and pediatric oncology 1998-12, Vol.31 (6), p.471-474
Main Authors: Himelstein, Bruce P., Asada, Naohiro, Carlton, Martha R., Collins, Margaret H.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Over 80% of patients with osteosarcoma treated with excision alone develop pulmonary metastases, suggesting that the majority of patients with this disease harbor “micrometastases” at diagnosis. There are no histologic or molecular variables which can predict the presence or absence of micrometastasis. Matrix metalloproteinases (MMPs) are a class of matrix‐ and basement membrane‐degrading enzymes whose expression is associated with tumor cell invasive and metastatic behavior. One of these enzymes, MMP‐9 or gelatinase B, is expressed in developing and remodeling bone and in osteosarcoma cell lines. We speculated that MMP‐9 expression might be associated with the micrometastatic behavior of osteosarcoma. Procedure We examined a series of pediatric primary osseous osteosarcomas and metastases for the expression of MMP‐9, using a monoclonal antibody. Results We found intense MMP‐9 immunostaining in most tumor cells in all samples of pretreatment osteosarcomas. In all postchemotherapy resection samples, tumor cells stained similarly, but there were fewer positively staining cells overall. In 4 of 5 metastastic lesions examined, intense immunostaining for MMP‐9 was detected. Conclusions These results suggest that MMP‐9 expression is common in osteosarcoma, and that further study of the role of MMP‐9 in pediatric osteosarcoma behavior is warranted. Med. Pediatr. Oncol. 31:471–474, 1998. © 1998 Wiley‐Liss, Inc.
ISSN:0098-1532
1096-911X
DOI:10.1002/(SICI)1096-911X(199812)31:6<471::AID-MPO2>3.0.CO;2-M